Physician profile
Seth M Keating
NPI 1023663614
$1,495.59
in general payments reported to CMS, 2019-2025
22 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.91 · 2022: $295 · 2023: $484 · 2024: $512 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.33 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.28 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $267.03 | 2023-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $135.50 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Glaxosmithkline, LLC. | $118.42 | 2022-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $84.61 | 2022-2024 | Jornay Pm |
| Lilly USA, LLC | $80.96 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Organon LLC | $71.27 | 2021-2023 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $64.95 | 2022-2024 | Abilify Maintena, Rexulti |
| Mylan Specialty L.P. | $62.56 | 2022-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $54.64 | 2023-2024 | Verquvo, Vaxneuvance, Vaxelis |
| Novo Nordisk INC | $30.31 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $26.69 | 2021-2025 | Breztri |
| Corium, LLC | $25.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.48 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $19.89 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.45 | 2024 | Venaseal |
| Pfizer INC. | $19.19 | 2025 | |
| Axsome Therapeutics, INC. | $17.70 | 2025 | Auvelity |
| Cranial Technologies, INC | $16.39 | 2023 | Doc Band |
| Ars Pharmaceuticals Operations, INC. | $15.31 | 2025 | Neffy |
| Astellas Pharma US INC | $15.25 | 2024 | Veozah |
| Tactile Systems Technology INC | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Keating listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.